Compare Invesco DB Commodity Index Tracking Fund (DBC) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco DB Commodity Index Tracking Fund vs Johnson & Johnson — how do they compare? Invesco DB Commodity Index Tracking Fund trades at $30.09, while Johnson & Johnson trades at $260.51 (market cap $626.09B). The key difference: Johnson & Johnson pays a 2.06% dividend while Invesco DB Commodity Index Tracking Fund pays none. Which is the better fit depends on your goals.
| DBC | JNJ | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $31.69 | $267.24 |
52-Week Low | $21.62 | $172.78 |
Market Cap | — | $626.09B |
Volume | — | 6,156,228 |
Enterprise Value | — | $654.37B |
Dividend Yield | — | 2.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DBC trades at $30.11, up 0.6% with a bullish technical signal from moving averages. The stock shows neutral oscillators with RSI at 59.40, while support and resistance cluster around $30. Recent news highlights commodities ETFs gaining attention as inflation hedges, with articles discussing broad commodity exposure and portfolio strategies.
The outlook for DBC appears cautiously optimistic given technical momentum and commodity market interest. Key risks include commodity price volatility and geopolitical tensions affecting supply chains. Investment opportunity lies in potential inflation hedging benefits, though fundamental metrics remain unavailable for deeper analysis.
Johnson & Johnson (JNJ) trades at $260.88, down 0.36% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net margin of 21.48% and ROE of 25.74%, though valuations like a P/E of 30.14 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 64-year dividend growth streak, with analyst consensus leaning bullish.
Outlook remains positive with a consensus price target of $284.50, offering potential upside, but risks include legal challenges and high debt-to-asset ratio of 24.06% in 2025. Investors benefit from steady dividends and defensive positioning in healthcare, though valuation multiples may limit near-term gains amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco DB Commodity Index Tracking Fund
DBC is a diversified commodity ETF that tracks the DBIQ Optimum Yield Diversified Commodity Index. It invests in futures contracts for 14 heavily traded commodities, including crude oil, gold, and corn, while optimizing for yield and roll costs.
Read more on DBC →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
